PVLA vs. WVE, RCUS, MLYS, SYRE, PAHC, AKBA, COLL, SNDX, NRIX, and NAGE
Should you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Wave Life Sciences (WVE), Arcus Biosciences (RCUS), Mineralys Therapeutics (MLYS), Spyre Therapeutics (SYRE), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Nurix Therapeutics (NRIX), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry.
Palvella Therapeutics vs.
Palvella Therapeutics (NASDAQ:PVLA) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Palvella Therapeutics presently has a consensus target price of $46.29, indicating a potential upside of 79.75%. Wave Life Sciences has a consensus target price of $20.50, indicating a potential upside of 182.56%. Given Wave Life Sciences' higher probable upside, analysts clearly believe Wave Life Sciences is more favorable than Palvella Therapeutics.
40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Palvella Therapeutics has higher earnings, but lower revenue than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.
Palvella Therapeutics has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500.
In the previous week, Wave Life Sciences had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 8 mentions for Wave Life Sciences and 6 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.45 beat Wave Life Sciences' score of 1.37 indicating that Palvella Therapeutics is being referred to more favorably in the media.
Wave Life Sciences received 354 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 67.83% of users gave Wave Life Sciences an outperform vote.
Palvella Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Palvella Therapeutics' return on equity of -80.93% beat Wave Life Sciences' return on equity.
Summary
Wave Life Sciences beats Palvella Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Palvella Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palvella Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PVLA) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy PVLA Stock Free PVLA Stock Alerts